RBC Capital initiated coverage of Axsome Therapeutics with an Outperform rating and $126 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AXSM:
- Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
- Axsome Therapeutics price target raised to $173 from $162 at Ladenburg
- Axsome Therapeutics price target raised to $95 from $80 at BofA
- Axsome Therapeutics provides 2024 development pipeline anticipated milestones
- Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones